About Us
Projects and Technology
Governance
Investors
Media
Contact

About Us
Projects and Technology
Corporate Governance
Investors
Media
Contact

Financial Reports and Presentations

2025

2017
2016
2015
2014
2012
2011
2010
2009
2007
All years

Other

Interim reports
Annual reports
Presentations
Other
All types

	Webcast
November 24, 2025Vivesto - Management provides business update on Paccal Vet and Cantrixil programs
November 20, 2025Interview DNB Carnegie

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

Take me there

About Us
Projects and Technology
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors. Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE).

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com